Eluxadoline for treating irritable bowel syndrome with diarrhoea

Summary

As part of the NICE Single Technology Assessment (STA) process we are critically reviewing the submission of the pharmaceutical company on the current evidence for the clinical and cost-effectiveness of Eluxadoline for treating irritable bowel syndrome with diarrhoea.

Contact

Miriam Brazzelli; m.brazzelli@abdn.ac.uk

Status

Completed - NICE guidance published 30 August 2017.